Omeros Corporation (OMER)Healthcare | Biotechnology | Seattle, United States | NasdaqGM
10.01 USD
-0.27
(-2.626%) ⇩
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 6:51 a.m. EDT
The long-term outlook is severely compromised by a brutal multi-year decline; the stock has lost nearly 69% of its value over the last nine years, with the last two years showing consecutive negative returns. Despite a recent commercial rollout exceeding expectations, the market has priced in significant structural deterioration, reflected in negative gross and operating margins and a negative book value. The balance sheet is fragile, with debt significantly outweighing cash reserves. While the short-term chart shows some recent recovery and a single analyst 'Buy' rating, the underlying business fundamentals—negative earnings, shrinking revenue, and a deteriorating competitive moat—make this a high-risk speculative vehicle rather than a sound investment. The lack of any dividend history further limits its utility as a defensive holding. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.304084 |
| AutoETS | 0.304571 |
| MSTL | 0.307203 |
| AutoTheta | 0.326480 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 28% |
| H-stat | 6.51 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.104 |
| Excess Kurtosis | -0.44 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.148 |
| Market Cap | 724,477,312 |
| Trailing P/E | 8.78 |
| Forward P/E | -64.58 |
| Beta | 2.55 |
| Profit Margins | 871.02% |
| Website | https://www.omeros.com |
As of July 11, 2026, 6:51 a.m. EDT: Speculators are positioning heavily for downside protection, evidenced by massive open interest in deep out-of-the-money puts (strikes at $3, $4, and $7) across multiple expirations, often with implied volatility spikes suggesting fear of a crash. Conversely, call activity is concentrated near the money ($10-$12 strikes) or at very high strikes ($25-$30), indicating a speculative 'lottery ticket' mentality rather than a conviction bet on a near-term rally. The imbalance suggests traders are hedging against a drop while waiting for a binary event to drive the price up.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.6157761 |
| Address1 | The Omeros Building |
| Address2 | 201 Elliott Avenue West |
| All Time High | 30.23 |
| All Time Low | 0.92 |
| Ask | 12.83 |
| Ask Size | 2 |
| Audit Risk | 8 |
| Average Daily Volume10 Day | 2,485,670 |
| Average Daily Volume3 Month | 1,777,129 |
| Average Volume | 1,777,129 |
| Average Volume10Days | 2,485,670 |
| Beta | 2.55 |
| Bid | 7.21 |
| Bid Size | 2 |
| Board Risk | 9 |
| Book Value | -0.88 |
| City | Seattle |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 10.01 |
| Current Ratio | 3.034 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 10.22 |
| Day Low | 9.94 |
| Display Name | Omeros |
| Earnings Call Timestamp End | 1,778,704,200 |
| Earnings Call Timestamp Start | 1,778,704,200 |
| Earnings Timestamp | 1,778,702,400 |
| Earnings Timestamp End | 1,786,651,200 |
| Earnings Timestamp Start | 1,786,651,200 |
| Ebitda | -104,334,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -7.819 |
| Enterprise To Revenue | 82.459 |
| Enterprise Value | 815,768,320 |
| Eps Current Year | 0.38 |
| Eps Forward | -0.155 |
| Eps Trailing Twelve Months | 1.14 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 11.4022 |
| Fifty Day Average Change | -1.3921995 |
| Fifty Day Average Change Percent | -0.122099206 |
| Fifty Two Week Change Percent | 161.5776 |
| Fifty Two Week High | 17.65 |
| Fifty Two Week High Change | -7.6399994 |
| Fifty Two Week High Change Percent | -0.43286118 |
| Fifty Two Week Low | 3.34 |
| Fifty Two Week Low Change | 6.67 |
| Fifty Two Week Low Change Percent | 1.997006 |
| Fifty Two Week Range | 3.34 - 17.65 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,255,008,600,000 |
| Float Shares | 69,800,964 |
| Forward Eps | -0.155 |
| Forward P E | -64.58064 |
| Free Cashflow | 181,015,872 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 175 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | -1.90488 |
| Gross Profits | -18,845,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.03557 |
| Held Percent Institutions | 0.44567 |
| Implied Shares Outstanding | 72,375,355 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington. |
| Long Name | Omeros Corporation |
| Market | us_market |
| Market Cap | 724,477,312 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_32388 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | 84,006,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 724,477,303 |
| Number Of Analyst Opinions | 1 |
| Open | 10.155 |
| Operating Cashflow | -94,759,000 |
| Operating Margins | -1.76094 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Peg Ratio | 0.81 |
| Phone | 206 676 5000 |
| Pre Market Change | -0.020000458 |
| Pre Market Change Percent | -0.19980477 |
| Pre Market Price | 9.99 |
| Pre Market Time | 1,784,016,019 |
| Previous Close | 10.28 |
| Price Eps Current Year | 26.342106 |
| Price Hint | 2 |
| Price To Book | -11.375 |
| Price To Sales Trailing12 Months | 73.23131 |
| Profit Margins | 8.7102 |
| Quick Ratio | 2.479 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.27 |
| Regular Market Change Percent | -2.62645 |
| Regular Market Day High | 10.22 |
| Regular Market Day Low | 9.94 |
| Regular Market Day Range | 9.94 - 10.22 |
| Regular Market Open | 10.155 |
| Regular Market Previous Close | 10.28 |
| Regular Market Price | 10.01 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 1,220,291 |
| Return On Assets | -0.25235 |
| Revenue Per Share | 0.148 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 6 |
| Shares Outstanding | 72,375,355 |
| Shares Percent Shares Out | 0.2091 |
| Shares Short | 15,136,140 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 16,271,790 |
| Short Name | Omeros Corporation |
| Short Percent Of Float | 0.2168 |
| Short Ratio | 6.21 |
| Source Interval | 15 |
| State | WA |
| Symbol | OMER |
| Target High Price | 33.0 |
| Target Low Price | 33.0 |
| Target Mean Price | 33.0 |
| Target Median Price | 33.0 |
| Total Cash | 135,316,000 |
| Total Cash Per Share | 1.87 |
| Total Debt | 226,607,008 |
| Total Revenue | 9,893,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 1.14 |
| Trailing P E | 8.780702 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 10.51695 |
| Two Hundred Day Average Change | -0.5069494 |
| Two Hundred Day Average Change Percent | -0.048203085 |
| Type Disp | Equity |
| Volume | 1,220,291 |
| Website | https://www.omeros.com |
| Zip | 98,119 |